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Abstract 
Background 
Coronary heart disease (CHD) mortality in England fell by 36% between 2000 and 2007 
and it is estimated that approximately 50% of the fall was due to improved treatment 
uptake.  Marked socio-economic inequalities in CHD mortality in the United Kingdom 
(UK) remain, with higher age-adjusted rates in more deprived groups. Inequalities in the 
persistence of medication for primary and secondary prevention of CHD may contribute 
to the observed social gradient and we investigated this possibility in the population of 
Wales (UK).  
 
Methods and findings 
An electronic cohort of individuals aged over 20 (n = 1,199,342) in Wales (UK) was 
formed using linked data from primary and secondary care and followed for six years 
(2004-2010). We identified indications for medication (statins, aspirin, ACE inhibitors, 
clopidogrel) recommended in UK National Institute for Clinical Excellence (NICE) 
guidance for CHD (high risk, stable angina, stable angina plus diabetes, unstable angina, 
and myocardial infarction) and measured the persistence of indicated medication (time 
from initiation to discontinuation) across quintiles of the Welsh Index of Multiple 
Deprivation, an area-based measure of socio-economic inequality, using Cox regression 
frailty models. In models adjusted for demographic factors, CHD risk and comorbidities 
across 15 comparisons for persistence of the medications, none favoured the least 
deprived quintile, two favoured the most deprived quintile and 13 showed no significant 
differences.  
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Conclusions 
During our study period (2004-2010) we found no significant evidence of socio-
economic inequality in the persistence of recommended medication for primary and 
secondary prevention of CHD.  
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Introduction 
Although coronary heart disease (CHD) mortality has fallen in recent decades in the UK 
and other high-income countries a social gradient persists, with a higher age-adjusted 
mortality in more socioeconomically deprived groups [1]. An IMPACT modelling study 
estimating the proportions of the fall in CHD mortality attributable to changes in risk 
factors or treatments (effectiveness and provision) found that in England and Wales, 
between 1981 and 2000, 58% of the fall in CHD mortality could be attributed to 
population-level reduction in major risk factors and 42% to treatments [2].  An IMPACT 
study of the period 2000-2007 in England, during which CHD mortality fell by 36%, 
estimated that improved uptake of treatments accounted for approximately 50% of the 
fall [3], with lipid-lowering therapy accounting for 14%. 
 
There is an association between the degree of compliance with CHD-related medication 
and CHD outcomes that is not only due to the ‘healthy adherer’ effect – the tendency for 
individuals with good medication adherence to have generally healthier lifestyles [4,5,6].  
There is also evidence that better medication compliance is associated with relative 
affluence [7] and that this applies to lipid-lowering therapy in CHD prevention [8-11]. 
 
A review of papers published between 1997 and 2005 that examined persistence of 
medication for hypertension and dyslipidaemia observed that few studies explicitly stated 
the definition of persistence used, and that different measures of persistence were 
employed [12]. A meta-analysis of papers published between 2000 and 2005 examining 
compliance with medication for hypertension, diabetes and dyslipidaemia reported that 
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different measures of persistence used over different time frames yielded widely differing 
results [4].  Studies of medication compliance have used definitions and terminology 
differently (compliance sometimes regarded as synonymous with adherence, and 
sometimes as including both adherence and persistence) and therefore standard 
definitions are proposed [12,13], clarifying that adherence is the proportion of prescribed 
doses taken in the prescribed time interval and persistence is the accumulation of time 
from the initiation of therapy to discontinuation of therapy.  
Although health care in the UK, including Wales, is publicly funded and free at the point 
of delivery, the concept of the ‘inverse care law’ [14] (more deprived groups having 
greater health care needs yet receiving poorer health care) has been influential in public 
health medicine in the UK. Evidence from some UK studies suggested that more socio-
economically deprived groups received poorer health care for cardiovascular disease 
[15,16]. Our previous study of the overall pathway of  CHD health care in the population 
of Wales [17] identified indications for recommended interventions, examined whether 
these interventions were received, and measured time to their delivery. The result showed 
little evidence of inequity (inequality to the disadvantage of more deprived groups) other 
than in relation to revascularization procedures. The analyses did not examine whether 
recommended interventions continued to be received appropriately and therefore did not 
exclude the possibility of inequity in medication persistence. We investigated that 
possibility  in the same cohort of over one million individuals during the study period, 
2004-2010, measuring the accumulation of time from initiation to discontinuation of  
recommended medication (persistence). As in our previous study [17] the 
recommendations for medication were those of national guidelines in primary and 
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secondary prevention of CHD, and we used area-based measures of socio-economic 
deprivation. Our data enabled us to identify indications for medication in individuals, to 
specify the start date of each indication, and to use a time-to-event survival technique 
directly measuring the accumulation of time from initiation to discontinuation of therapy. 
We were able to adjust for relevant covariates and the data used (with the exception of 
the inference of deprivation from area level measures) was available at the individual 
level We are not aware of any other study of this size addressing this issue in any UK 
population. 
 
Methods   
The analyses were carried out within the Secure Anonymized Information Linkage 
databank (SAIL) at Swansea University [18,19]. The system allows researchers to link 
primary care data, hospital activity data, and mortality data to inform the clinical history 
of individuals.   
Permission to undertake the analyses was obtained from the Information Governance 
Review Panel at SAIL in line with the Collaborative Review System (project reference 
number 0156).  
 
Datasets  
We defined a retrospective cohort of individuals aged 20 or over, resident in Wales and 
registered with SAIL-submitting general practices between 1 January 2004 and 31 
December 2010.  Individuals reaching the age of 20 were added to the cohort at annual 
time points. Routine data from the Welsh Demographic Service, Patient Episode Data for 
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Wales (PEDW) hospital admission data (ICD 10 and Office of Population and Censuses 
codes for CHD-related hospital episodes and procedures), and primary care data (Read 
codes for diagnosis, investigation and treatment of CHD and the prescribing of 
antihypertensive, lipid-lowering and anti-platelet therapy) were extracted to form a linked 
dataset. If an individual died or ceased to be registered with a SAIL-submitting practice 
this was treated as a censoring event. The primary care data available for our study was 
available only from SAIL-submitting practices, covering approximately 40% of the 
population of Wales. There is no available evidence that these practices were 
unrepresentative. The distribution of urban and rural residency of the population 
resembled that of Wales as a whole. Comparison with Office of National Statistics (ONS) 
mid-year data (2004) for the whole of Wales showed small differences in age 
distribution, our cohort having 1.2% fewer in the proportion aged over 40. Comparison of 
the socio-economic distribution of our study population with that of Wales as a whole 
showed that quintiles 1 and 3 were over-represented (21.3% and 22.94% respectively) 
and quintiles 2, 4 and 5 were under-represented (18.34%, 18.72% and 18.55% 
respectively). 
 
Assessment of socioeconomic inequalities 
The Welsh Index of Multiple Deprivation (WIMD) (2008) for the individual’s residence 
was assessed at the Lower Super Output Area (LSOA) (mean population 1500) as a 
measure of socioeconomic deprivation. The 2008 WIMD is based on the resident’s 
income, employment status, education, housing, health and geographical access to 
services [20].  
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Inequalities were examined by comparing WIMD quintile 5 (most deprived) to quintile 1 
(least deprived).  
 
Indicated medication. 
The criteria for indicated medication were based on the interventions recommended in 
UK National Service Frameworks (NSFs) for CHD [21,22] and National Institute for 
Health and Care Excellence (NICE) guidelines relating to the study period [23-27]. In 
relation to primary prevention, the level of CHD event risk at which statin treatment was 
recommended by NSF and NICE guidelines was 20% over ten years [27]. Components of 
the risk score were systolic blood pressure, body mass index (BMI), smoking status, and 
cholesterol: high density lipoprotein (HDL) ratio. Those whose risk of CHD was 
designated high on this basis are referred to as ‘risk assessed high’ (see table 1) and those 
at high risk because of a diagnosis of cerebrovascular disease, peripheral vascular disease 
or diabetes are referred to as ‘high-risk diagnosis’.  
 
We developed a set of algorithms based on Read codes [28] to identify all individuals for 
whom medication in primary and secondary prevention of CHD was indicated, and we 
examined provision and persistence of that medication. The 15 interventions for which 
we made comparisons between deprivation groups that are shown in table 1. We did not 
make comparisons for the numerous possible combinations of medications used in 
management of hypertension.  
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Our routine data did not provide information on individuals’ contraindications to 
medication, or refusal of treatment. Data were not available on in-patient prescribing and 
our examination of prescription of medication was confined to the period after 
individuals left hospital.  
 
Although the recommended interval between of repeat prescriptions in UK general 
practice is usually 28 days there is variation in practice, and there is evidence that in 
Wales during our study period a minority of repeat prescriptions were issued at intervals 
longer than longer 28 days [29,30].  We made a simplifying assumption and designated 
the point at which persistence of medication had lapsed as the last issue of that 
prescription where it occurred at least 56 days prior to the end of the observation period 
for that individual.  
 
Covariates  
We examined a number of potentially confounding factors determined at the time-point at 
which the indication for the medication appeared. They were selected on the basis of 
availability and evidence from previous studies [17] . Covariates available included 
demographic factors (age, sex ); risk-factors (systolic blood pressure, body mass index, 
smoking status, cholesterol: HDL ratio); co-morbidities based on the Charlson co-
morbidity index [31] collapsed to a binary variable because some components were 
already considered as covariates (CHD, cerebrovascular disease and diabetes); and the 
Framingham non-laboratory risk assessment score (comprising sex, age, systolic blood 
pressure, BMI, smoking status, reported diabetic status, and current treatment for 
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hypertension) [32]. We accounted for previous indications for the same medication: for 
example statins indicated by angina might previously have been indicated by risk-
assessment.  
 
Statistical methods 
We used a Cox model with random effects (frailty models) to examine the persistence of 
CHD-related medication, measuring the length of time from initiation until the issue of 
the last prescription for medication that appeared still to be indicated (with at least 56 
days without a prescription prior to the end of the observation period required to define a 
last prescription).  For each of the comparisons we produced Kaplan-Meier plots that 
enabled treatment of censoring events. 
We fitted the individual’s general practice or admitting hospital modelled as random 
effects, to allow for unobserved hospital or primary care specific factors that might cause 
clustering. The type 1 error probability was set to 0.05 for all analyses. Modelling was 
performed using the coxme package in R [30].  
 
We used multiple imputations (n = 20 imputed datasets) with chained equations to impute 
values for missing covariates: systolic blood pressure, BMI, cholesterol:HDL ratio, 
smoking status and admission type, including all outcomes in the prediction model. We 
performed sensitivity analyses, re-running analyses using the 2001 Townsend deprivation 
quintiles and the 1991 Framingham assessment tool.  
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Results 
The initial cohort comprised 1,201,399 subjects. After exclusion of those with an 
incorrectly coded date of birth (n = 202), absent coding for gender (n = 7) or with 
discontinuous registration with SAIL (n = 1848) the cohort was reduced to 1,199,342.   
 
Table 1: Numbers of medications initiated for each indication and discontinued within 
observation period by indication and medication type 
Original indication 
Medication 
initiated 
Number 
initiating 
medication 
Number 
stopping 
medication 
Risk assessed high Statin 33228 5378 
High-risk diagnosis Statin 29208 4041 
Stable angina Statin 11231 1711 
Stable angina and diabetes Statin 6588 782 
Unstable angina Statin 9211 1341 
MI Statin 11380 1642 
Stable angina Aspirin 10704 2590 
Stable angina and diabetes Aspirin 5472 1056 
Unstable angina Aspirin 8663 1654 
MI Aspirin 11011 1889 
Stable angina and diabetes ACE inhibitor 5620 827 
Unstable angina ACE inhibitor 7860 1443 
MI ACE inhibitor 10772 1916 
Unstable angina Clopidogrel 5783 3419 
MI Clopidogrel 10133 6536 
 
 
Table 1 shows the number of medications initiated for each indication and the number of 
those treatments subsequently discontinued during the observation period. The pattern of 
discontinuation is shown in the panel of Kaplan-Meier plots (Figure 1). 
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One plot for each of the medications investigated is shown. The patterns shown for each 
of the drugs for these indications are reflected in very similar patterns for each drug for 
the other indications investigated.  Additional Kaplan-Meier plots for these indications 
are included in the supporting information for this paper; those shown are illustrative of 
the patterns observed. 
  
For statins, ACE inhibitors and aspirin, a gradual decrease in persistence was observed 
over the seven years of observation. At five years, 75% of individuals initiated on statins 
for ‘risk assessed high’ were still being prescribed the medication in each of the 
deprivation quintiles.  A similar pattern was observed for ACE inhibitors and aspirin, 
although the proportion of individuals still prescribed these medications at five years was 
slightly less than 75% for each of the quintiles.  For clopidogrel, the recommendation that 
applied during the period of our study [23] for 12 months of treatment is reflected in the 
pronounced decline in persistence at one year following initiation of therapy, with a 
gradual decline thereafter. Each of the plots shows a decline in persistence following the 
initial 28-day prescription, with this pattern most pronounced for clopidogrel. 
Importantly, no substantial differences in persistence are observed between deprivation 
quintiles. 
 
Figure 1: Panel of Kaplan-Meier plots for selected indications and medications 
showing the discontinuation in medication persistence across the seven year 
observation period.   
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Within each individual Kaplan-Meier plot, the survival curve is shown separately 
for each of the deprivation quintiles.  Quintile 1 (red) is the least deprived 
quintile. 
 
A summary of our results in the fully adjusted models is presented in table 2.  Two 
comparisons showed statistically significant differences: in individuals with a ‘high-risk 
diagnosis’ the persistence for statins favoured the most deprived quintile (HR 0.78,  
95% CI 0.70, 0.88), and in individuals who had a myocardial infarction (MI) the 
persistence for clopidogrel (during the 12-month period for which it was indicated post-
MI) also favoured the most deprived quintile (HR 0.86, 95% CI 0.78, 0.95). 
  
 
Table 2: Hazard ratios (HRs) and 95% confidence intervals (CIs) for the 
association between socioeconomic inequalities and discontinuation of indicated 
medication for CHD prevention. 
Hazard ratios (HRs) relate to discontinuation of medication during the indicated 
period. Hazard ratios less than 1 indicate that the most deprived quintile was less 
likely than the least deprived quintile to stop taking the medication for the given 
indication. HR adjusted for age, sex, smoking status, BMI, hypertension, 
cholesterol: HDL ratio, and comorbidities; for MI and unstable angina 
indications also adjusted for admission type and specialty.  
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Original indication Medication initiated 
Hazard ratio 
for 
comparison 
between 
quintile 5 and 
quintile 1 
(95% 
confidence 
interval) 
Statisticaly 
significant 
difference? Favours 
Risk assessed high Statin 
0.95 (0.86, 
1.05) No 
 
High-risk diagnosis Statin 
0.78 (0.70, 
0.88) Yes 
Most 
deprived 
Stable angina Statin 
1.06 (0.88, 
1.26) No 
 
Stable angina and diabetes Statin 
0.84 (0.65, 
1.09) No 
 
Unstable angina Statin 
1.04 (0.84, 
1.27) No 
 
MI Statin 
0.97 (0.80, 
1.18) No 
 
Stable angina Aspirin 
1.01 (0.88, 
1.17) No 
 
Stable angina and diabetes Aspirin 
0.86 (0.69, 
1.08) No 
 
Unstable angina Aspirin 
0.85 (0.71, 
1.02) No 
 
MI Aspirin 
1.13 (0.94, 
1.35) No 
 
Stable angina and diabetes ACE inhibitor 
1.10 (0.85, 
1.41) No 
 
Unstable angina ACE inhibitor 
1.14 (0.93, 
1.38) No 
 
MI ACE inhibitor 
1.15 (0.96, 
1.36) No 
 
Unstable angina Clopidogrel 
1.03 (0.91, 
1.17) No 
 
MI Clopidogrel 
0.86 (0.78, 
0.95) Yes 
Most 
deprived 
 
Use of the Framingham 1991 risk assessment tool and the Townsend deprivation 
quintiles in ours sensitivity analyses made only small differences to the estimated hazard 
ratios , and of the 15 comparisons the same two (for ‘high risk diagnosis’ and for MI) 
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significantly favoured quintile 5. For ‘high risk diagnosis’ the hazard ratio was 0.78 in the 
fully adjusted model, 0.79 in the Framingham 1991 risk assessment analysis and 0.82 in 
the Townsend quintiles analysis. For MI the hazard ratios in these analyses were 
respectively 0.86,0.86 and 0.88. In none of the models was there a significant difference 
in any of the 13 other comparisons and therefore the overall pattern remained unchanged 
in the sensitivity analyses. 
Discussion 
We found little evidence of socio-economic inequality in persistence of indicated 
medication in the primary and secondary prevention of CHD. Only two of the 15 
indicated medications showed a difference in persistence according to levels of socio-
economic deprivation, both having a longer persistence in the most deprived groups.  
 
Persistence of medication depends on healthcare-related factors, including administrative 
systems, the observing and recording of indications for medication, and individual 
prescription review [34,35].  The introduction in the UK in 2004 of the Quality and 
Outcomes Framework (QOF), a major public health intervention, incentivised such 
activities [36].  Persistence also depends on patient-factors including adverse reactions, 
emerging contra-indications, refusal of treatment, and comorbidities.  Our findings 
indicate that the overall effects of these factors (healthcare-related and patient-related) did 
not cause inequity in persistence of the medication we examined. 
 
Comparison with other studies 
  
17 
17 
 Our findings are consistent with those from a UK study on the use of statins after first 
myocardial infarction during the period 1997-2004 [8] that found approximately 80% of 
individuals continued to receive statins at one year and approximately 76% at 5-10 year 
follow-up.  
 
In a multinational, multicentre trial of individuals with acute coronary syndromes (ACS), 
1999-2003, discontinuation rates at six months were 8% for aspirin, 13% for statins, 20% 
for ACE inhibitors [37]. In a USA study individuals undergoing catheterization for CHD 
between 1998-2001 were found to have discontinuation rates at 12 months of 28% for 
ACE inhibitors and 18% for aspirin [38]. In a UK study of individuals after  MI (2003-
2009) the adjusted odds of being prescribed clopidogrel at 12 months were 53% for 
NSTEMI and 54% for STEMI [39].  
 
A number of large (> 30, 000 subjects) UK studies, ecological or population-based, have 
examined evidence of equity in use of CHD-related medication although none primarily 
examined persistence. Of the seven large studies using prescribing rates to examine lipid-
lowering therapy in primary prevention of CHD the results in four favoured the less 
deprived [40-34], two showed no difference [15,16] and one favoured the more deprived 
group [45]. Of eight large UK studies examining use of anti-platelet medication (aspirin 
and clopidogrel) in primary and/or secondary prevention of CHD the results in primary 
prevention in two studies favoured the less deprived [15,16], in one favoured the more 
deprived [46], and in two showed no difference [40,47]. In relation to anti-platelet 
medication in secondary prevention the results in one study favoured the less deprived 
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[15, in two favoured the more deprived [48,49], and in one showed no significant 
difference [50]. Four studies indicating inequity in lipid-lowering therapy in primary 
prevention were published between 1998 and 2004, [40-43], but a large individual-level 
study examining the increase in utilization of medication, but not examining persistence, 
found no evidence of inequity in secondary prevention of CHD in the UK between 1999 
and 2007 [49]. Our study found that in both primary and secondary prevention of CHD 
between 2004 and 2011 there was no significant evidence of inequity in medication 
persistence.  
 
 Policy implications  
Our study period coincided with a relatively rapid improvement in the UK in a range of 
clinical activity indicators, including those related to the recording and delivery of CHD-
related primary care [51]. This was attributed partly to the introduction in 2000 of the 
National Service Framework for CHD in England (2001 in Wales) and in 2004 of the 
Quality Outcomes Framework (QOF) [36]. Our findings suggest that if these 
improvements extended to the appropriate persistence of medication in CHD healthcare 
they did so equitably.  
 
Strengths of the study 
We based our study on data from a large number of individuals (more than one million) 
and used a time-to-event methodology developed to address population-level analysis of 
healthcare use adjusted for need.  
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Our study examined a health service in which healthcare is free at the point of delivery, 
and in Wales, unlike other parts of the UK, there is no charge for prescriptions. It has 
been shown in the USA that a lower level of insurance cover, and consequently higher 
financial cost to the individual, is associated with poorer adherence to medication used in 
secondary prevention of CHD [52]. The integrated system of healthcare in the UK differs 
significantly from systems such as those seen in the USA and results from the study of 
our population may form a useful comparator for studies in other healthcare systems.  
 
Limitations of the study 
Because of the complexity of recommended medication for hypertension with numerous 
potential permutations, and because of the difficult in distinguishing their clinical 
indications in an individual (as when a diuretic or a beta blocker might have been 
prescribed for reasons other than hypertension) we did not include antihypertensives in 
this analysis, although we analysed the use of ACE inhibitors in relation to stable angina 
with diabetes, unstable angina, and MI.  
Area-based measures of socio-economic status are known to underestimate inequalities 
and their use may therefore have reduced our ability to detect inequalities. 
Conclusions  
We found no significant evidence of inequity in medication persistence in primary and 
secondary prevention of CHD.  
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